Abstract:RNA editing offers the opportunity to introduce either stable or transient modifications to nucleic acid sequence without permanent off-target effects, but installation of arbitrary edits into the transcriptome is currently infeasible. Here, we describe Programmable RNA Editing & Cleavage for Insertion, Substitution, and Erasure (PRECISE), a versatile RNA editing method for writing RNA of arbitrary length and sequence into existing pre-mRNAs via 5′ or 3′ trans-splicing. In trans-splicing, an exogenous template is introduced to compete with the endogenous pre-mRNA, allowing for replacement of upstream or downstream exon sequence. Using Cas7-11 cleavage of pre-mRNAs to bias towards editing outcomes, we boost the efficiency of RNA trans-splicing by 10–100 fold, achieving editing rates between 5–50% and 85% on endogenous and reporter transcripts, respectively, while maintaining high-fidelity. We demonstrate PRECISE editing across 11 distinct endogenous transcripts of widely varying expression levels, showcasing more than 50 types of edits, including all 12 possible transversions and transitions, insertions ranging from 1 to 1,863 nucleotides, and deletions. We show high efficiency replacement of exon 4 of MECP2, addressing most mutations that drive the Rett Syndrome; editing of SHANK3 transcripts, a gene involved in Autism; and replacement of exon 1 of HTT, removing the hallmark repeat expansions of Huntington′s disease. Whole transcriptome sequencing reveals the high precision of PRECISE editing and lack of off-target trans-splicing activity. Furthermore, we combine payload engineering and ribozymes for protein-free, high-efficiency trans-splicing, with demonstrated efficiency in editing HTT exon 1 via AAV delivery. We show that the high activity of PRECISE editing enables editing in non-dividing neurons and patient-derived Huntington’s disease fibroblasts. PRECISE editing markedly broadens the scope of genetic editing, is straightforward to deliver over existing gene editing tools like prime editing, lacks permanent off-targets, and can enable any type of genetic edit large or small, including edits not otherwise possible with existing RNA base editors, widening the spectrum of addressable diseases.

SPLICER: A Highly Efficient Base Editing Toolbox That Enables Therapeutic Exon Skipping

Rewriting endogenous human transcripts with -splicing

RNA Exon Editing: Splicing the way to treat human diseases

Programmable RNA writing with trans-splicing

CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements

OLIGONUCLEOTIDES TARGETING THE SPLICE ACCEPTOR SITE DOWNSTREAM OF A MICROEXON AS AN INNOVATIVE THERAPY FOR AUTISM

Adenine Base Editor–mediated Splicing Remodeling Activates Noncanonical Splice Sites

Specificity, synergy, and mechanisms of splice-modifying drugs

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Antisense-mediated exon inclusion.

A split prime editor with untethered reverse transcriptase and circular RNA template

Base editing as a genetic treatment for spinal muscular atrophy

Development and validation of AI/ML derived splice-switching oligonucleotides

SpliceTools, a Suite of Downstream RNA Splicing Analysis Tools to Investigate Mechanisms and Impact of Alternative Splicing

Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing

Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing

Systematic deletion of symmetrical CFTR exons reveals new therapeutic targets for exon skipping antisense oligonucleotides

A Novel Base Editor SpRY-ABE8eF148A Mediates Efficient A-to-G Base Editing with a Reduced Off-Target Effect

A New Compact Adenine Base Editor Generated Through Deletion of HNH and REC2 Domain of SpCas9

Decrypting the Information Exchange Pathways across the Spliceosome Machinery